Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435634 | 0.95 | FFAR4 (0.46) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL438249 | 0.82 | PLA2G10 (0.49) | MAPK1FFAR1 | |
| SCHEMBL435644 | 0.81 | RXRA (0.58) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL437655 | 0.80 | RXRA (0.52) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL2981839 | 0.79 | MAPT (0.61) | RXRARXRBRXRG | |
| SCHEMBL2985729 | 0.79 | MAPT (0.52) | RXRARXRBRXRG | |
| SCHEMBL438245 | 0.79 | RXRA (0.51) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL10301521 | 0.78 | RXRA (0.50) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL2997341 | 0.77 | MAPT (0.59) | RXRARXRBRXRGHDAC3MAPK1 | |
| SCHEMBL436570 | 0.77 | RXRA (0.49) | RXRARXRBRXRGHDAC3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383951-A1 | METHODS FOR TREATING DEPENDENCE | BIOTIE THERAPIES INC (US) | 2020-12-10 | — | — | US | claimed |
| EP-3251670-A1 | METHODS FOR TREATING DEPENDENCE | Biotie Therapies, Inc. (US) | 2017-12-06 | — | — | EP | claimed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | claimed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | claimed |
| WO-2010124089-A2 | METHODS FOR TREATING DEPENDENCE | SYNOSIA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2182804-A1 | METHODS FOR TREATING DEPENDENCE | Synosia Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090041800-A1 | Methods for Treating Dependence | SYNOSIA THERAPEUTICS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2009021055-A1 | METHODS FOR TREATING DEPENDENCE | SYNOSIA THERAPEUTICS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20200383951-A1 | METHODS FOR TREATING DEPENDENCE | BIOTIE THERAPIES INC (US) | 2020-12-10 | — | — | US | disclosed |
| EP-3210983-B1 | BENZOTHIAZOLE DERIVATIVES | BIOTIE THERAPIES INC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2443114-B1 | BENZOTHIAZOLE DERIVATIVES | BIOTIE THERAPIES INC (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3251670-A1 | METHODS FOR TREATING DEPENDENCE | Biotie Therapies, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3210983-A1 | BENZOTHIAZOLE DERIVATIVES | Biotie Therapies, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2182804-B1 | METHODS FOR TREATING DEPENDENCE | BIOTIE THERAPIES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2009021055-A1 | METHODS FOR TREATING DEPENDENCE | SYNOSIA THERAPEUTICS, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090041800-A1 | Methods for Treating Dependence | SYNOSIA THERAPEUTICS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | RXRA 3768/4885RXRB 3278/4885RXRG 3367/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | RXRA 2625/4885RXRB 2005/4885RXRG 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.